Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Linkoeping | OTHER |
Not provided
Not provided
Not provided
Not provided
A biobank within the Swedish national heart failure quality registry SwedeHF.
The national heart failure quality registry SwedeHF started in 2003. It is the world's largest continuous HF registry enrolling clinician-judged HF (regardless of LVEF) at time of hospital or clinical visit. Eighty variables are entered into an electronic database managed by the Uppsala Clinical Research Center (UCR). There are >140,000 registrations from >110,000 unique patients from 70 hospitals in Sweden.
University hospitals in Sweden with access to central biobanking will collect a high-quality biobank linked to SwedeHF consisting of blood plasma, whole blood and urine enabling genetic, proteomic and metabolomic analyses as well as analyses of different biomarkers of interest for HF patients. This will provide unique opportunities for future research within the national SwedeHF registry.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Identify responders to guideline-directed medical therapy | To identify which patient will be a non-responder resulting in a poor outcome, despite being on recommended treatment according to guidelines. | 2 and 5 years |
| Differences in morbidity between responders and non-responders to guideline-directed medical therapy | To characterize differences between responders and non-responders in terms of morbidity after 2-years follow-up. | 2 years |
| Differences in mortality between responders and non-responders to guideline-directed medical therapy | To characterize differences between responders and non-responders in terms of mortality after 2-years follow-up. | 2 years |
| Predictors of responders and non-responders to guideline-directed medical therapy | To integrate information regarding clinical characteristics, diagnostic markers and genetics to determine underlying mechanisms behind different responses to treatment. | 2 and 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Differences between responders and non-responders regarding mortality | To evaluate the differences between HFrEF and HFpEF patients in terms of mortality and after 2 and 5 years follow-up, respectively. | 2 and 5 years |
| Differences between responders and non-responders regarding morbidity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
PAtients with heart failure in Sweden with a registration in SwedeHF.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Camilla Hage, Ass prof | Contact | +46 (0)703340660 | camilla.hage@regionstockholm.se | |
| Ulf Dahlström, Prof | Contact | ulf.dahlstrom@liu.se |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska University hospital | Recruiting | Stockholm | 17164 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41961636 | Derived | Hage C, Andersson T, Christersson C, Linde C, Lund LH, Karlstrom P, Chatziapostolou D, Dagner V, Granstrom F, Gylling A, Jonsson A, Haglund P, Hogberg J, Odenstedt A, Viklund U, Magnusson M, Smith JG, Szabo-Soderberg B, Ostgard Thunstrom E, Dahlstrom U. An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics. ESC Heart Fail. 2026 Mar 3;13(2):xvag092. doi: 10.1093/eschf/xvag092. |
Not provided
Not provided
Data sharing will only be within investigators. Beyond study investigators data sharing requires new ethical approval.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma, serum, whole blood, urine
o evaluate the differences between HFrEF and HFpEF patients in terms of morbidity after 2 and 5 years follow-up, respectively. |
| 2 and 5 years |
| Predictors of mortality in responders and non-responders | To evaluate the differences in mortality between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets. | 2 and 5 years |
| Predictors of morbidity in responders and non-responders | To evaluate the differences in morbidity between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets. | 2 and 5 years |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided